Up­dat­ed: Roche pays Al­ny­lam $310M cash to part­ner on RNAi can­di­date for heart dis­ease

Roche is buy­ing in­to a mid-stage car­dio­vas­cu­lar drug can­di­date out of Al­ny­lam’s RNAi plat­form in a deal that starts with $310 mil­lion up­front and could add up to $2.8 bil­lion.

The two com­pa­nies will co-de­vel­op and co-com­mer­cial­ize the pro­gram, zilebe­sir­an, as a treat­ment of hy­per­ten­sion in pa­tients with high car­dio­vas­cu­lar risk and oth­er heart dis­eases by low­er­ing blood pres­sure.

In the US, the duo will split prof­its and loss­es equal­ly, while Roche will take on ex-US sales and pay Al­ny­lam a roy­al­ty in those re­gions. It al­so agreed to shoul­der 60% of the de­vel­op­ment costs for the first in­di­ca­tion, which will in­clude an ex­pen­sive car­dio­vas­cu­lar out­comes tri­al pri­or to fil­ing for ap­proval. Al­ny­lam will lead that joint ef­fort.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER